EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 3b

Ensembl ID : ENSDARG00000086214
Gene Symbol: NTRK3B
5 Cross references
198 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSDARG00000076694
Gene Symbol: NAMPT
6 Cross references
155 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase A

Ensembl ID : ENSDARG00000030598
Gene Symbol: NAMPTA
5 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSDARG00000043077
Gene Symbol: NISCH
5 Cross references
210 Possible Orthologues:

Nitric Oxide Synthase 2a, Inducible

Ensembl ID : ENSDARG00000026925
Gene Symbol: NOS2A
8 Enzyme and pathways 5 Cross references
160 Possible Orthologues:

Nitric Oxide Synthase 2b, Inducible

Ensembl ID : ENSDARG00000031976
Gene Symbol: NOS2B
5 Cross references
164 Possible Orthologues:

Notch Receptor 1a

Ensembl ID : ENSDARG00000103554
Gene Symbol: NOTCH1A
5 Cross references
195 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSDARG00000052094
Gene Symbol: NOTCH1B
5 Cross references
200 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSDARG00000052139
Gene Symbol: NOTCH3
5 Cross references
194 Possible Orthologues:

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1

Ensembl ID : ENSDARG00000105261
Gene Symbol: NFKB1
54 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Nuclear Factor, Erythroid 2-Like 2a

Ensembl ID : ENSDARG00000042824
Gene Symbol: NFE2L2A
5 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSDARG00000098439
Gene Symbol: NR1H3
18 Enzyme and pathways 5 Cross references
392 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).